To evaluate the buchylscoporamine for stop the motion of prostate during MRI examination.

To evaluate the buchylscoporamine for stop the motion of prostate during MRI examination. - Effect of buthylscoporamine in MRI examination

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021510

Enrollment

Registered

2016-03-17

Start date

2016-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with prostate cancer who treated using IMRT

Exclusion criteria

Exclusion criteria: risk of bleeding tendency

Design outcomes

Primary

Measure	Time frame
To evaluate the buchylscoporamine using MR images	—

Countries

Japan

Contacts

Public ContactOsamu Tanaka

Gifu Municipal Hospital Department of Radiation Oncology

c.bluered@gmail.com058-251-1101

Outcome results